Cardiothoracic & vascular anaesthesia
General vs. non-general anesthesia for transcatheter aortic valve replacement: A real-world target trial emulation study
Authors' conclusion
In this large real-world analysis, anesthetic strategy during TAVR was not associated with differences in mortality or most major complications through one year.
Study context
- Population
- Adults undergoing Transcatheter Aortic Valve Replacement (TAVR), January 2015 to December 2024after matching
- Participants
- 3,586 adults
- Exposure
- General anesthesia (GA) vs non-general anesthesia (NGA) for TAVR
- GAn = 1,793
- NGAn = 1,793reference
- Outcome
- All-cause mortality
- Follow-up
- 30, 90 and 365 days
Methodological detailstarget trial emulation, 1:1 propensity score matching, TriNetX Global Collaborative Network
- Target trial emulation
- 1:1 propensity score matching
- TriNetX Global Collaborative Network
Main finding
As reported in the abstract
30, 90, or 365 days
- All-cause mortality did not differ between GA and NGA at 30, 90, or 365 days
- Propensity-matched cohort
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Heart failure · 365 daysNominally higher | 1.44 (1.05–1.99) | P = 0.023 | |
| 0.512Hazard ratio (log scale) |
Stroke, MI, AKI, AF, major vascular complications, respiratory failure · 30, 90 and 365 days
- Similar across follow-up intervals
All-cause hospital readmission · 30 days
- NGA associated with lower readmission within 30 days; no differences at later follow-up
Original publication
General vs. non-general anesthesia for transcatheter aortic valve replacement: A real-world target trial emulation study. J Clin Anesth. Published 20 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →